# A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma

> **NCT01551459** · PHASE2 · COMPLETED · sponsor: **The Clatterbridge Cancer Centre NHS Foundation Trust** · enrollment: 124 (estimated)

## Conditions studied

- Metastatic Uveal Melanoma

## Interventions

- **DRUG:** Dacarbazine
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT01551459
- **Lead sponsor:** The Clatterbridge Cancer Centre NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2017-09
- **Final completion:** 2017-11
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2019-10-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01551459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01551459, "A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01551459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*